About: Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Analýza minimální reziduální nemoci (MRN) u protokolu ALL IC-BFM 2002 pro léčbu dětské ALL: Je možné vyhnout se testování MRN? (cs) The ALL IC-BFM 2002 protocol was created as an alternative to the MRD-based AIEOP-BFM ALL 2000 study, to integrate early response criteria into risk-group stratification in countries not performing routine PCR-based MRD testing. The ALL IC-BFM 2002 protocol was created as an alternative to the MRD-based AIEOP-BFM ALL 2000 study, to integrate early response criteria into risk-group stratification in countries not performing routine PCR-based MRD testing. (en)
Title	Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? (en) Analýza minimální reziduální nemoci (MRN) u protokolu ALL IC-BFM 2002 pro léčbu dětské ALL: Je možné vyhnout se testování MRN? (cs)
skos:prefLabel	Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? (en) Analýza minimální reziduální nemoci (MRN) u protokolu ALL IC-BFM 2002 pro léčbu dětské ALL: Je možné vyhnout se testování MRN? (cs)
skos:notation	RIV/00216208:11130/08:4138!RIV09-MZ0-11130___
http://linked.open...avai/riv/aktivita	P Z
http://linked.open...avai/riv/aktivity	P(NR8269), Z(MSM0021620813), Z(MZ0FNM2005)
http://linked.open...iv/cisloPeriodika	5
http://linked.open...vai/riv/dodaniDat	2009
http://linked.open...aciTvurceVysledku	Řezníčková, Leona Zdráhalová, Kateřina Valová, Taťjana Trka, Jan Mejstříková, Ester Starý, Jan Hrušák, Ondřej Froňková, Eva
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Karlova v Praze / 2. lékařská fakulta
http://linked.open...dnocenehoVysledku	379535
http://linked.open...ai/riv/idVysledku	RIV/00216208:11130/08:4138
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	acute lymphoblastic leukemia; minimal residual disease; risk-group stratification; immunoglobulin and T-cell receptor gene rearrangements; bone marrow morphology; acute lymphoblastic-leukemia; time quantitative pcr; gene rearrangements; clinical-significance; treatment response; prognostic value; concerted action; immunoglobulin; children; targets (en)
http://linked.open.../riv/klicoveSlovo	targets acute lymphoblastic leukemia prognostic value children treatment response immunoglobulin gene rearrangements acute lymphoblastic-leukemia clinical-significance concerted action minimal residual disease time quantitative pcr bone marrow morphology immunoglobulin and T-cell receptor gene rearrangements risk-group stratification
http://linked.open...odStatuVydavatele	GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV	[8F155D31992E]
http://linked.open...i/riv/nazevZdroje	Leukemia
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	8 (xsd:int)
http://linked.open...cetTvurcuVysledku	18 (xsd:int)
http://linked.open...vavai/riv/projekt	Polychromatic flow cytometry and regulation of aberrant expression from the perspective of Minimal Residual Disease
http://linked.open...UplatneniVysledku	2008
http://linked.open...v/svazekPeriodika	22
http://linked.open...iv/tvurceVysledku	Froňková, Eva Mejstříková, Ester Starý, Jan Trka, Jan Zdráhalová, Kateřina Hrušák, Ondřej Řezníčková, Leona Valová, Taťjana
http://linked.open...ain/vavai/riv/wos	000255797600013
http://linked.open...n/vavai/riv/zamer	The Molecular Basis of Childhood Malignancies and Therapeutic Applications Zdokonalení časné diagnostiky, prevence a léčby těžkých vrozených vývojových vad a chorob geneticky podmíněných či s genetickou dispozicí v prenatální a postnatální fázi vývoje
issn	0887-6924
number of pages	9 (xsd:int)
http://localhost/t...ganizacniJednotka	11130

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software